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Abstract
The forces that drive conversion of nascent protein to MHC class I-restricted
peptides remain unknown. We explored the fundamental property of overt
hydrophobicity as such a driver. Relocation of a membrane glycoprotein to the
cytosol via signal sequence ablation resulted in rapid processing of nascent protein
not because of the misfolded luminal domain but because of the unembedded
transmembrane (TM) domain which serves as a dose-dependent degradation motif.
Dislocation of the TM domain during the natural process of endoplasmic reticulumassociated degradation (ERAD) similarly accelerated peptide production, but in the
context of markedly prolonged processing that included non-nascent species. These
insights into intracellular proteolytic pathways and their selective contributions to
MHC class I-restricted peptide supply, may point to new approaches in rational
vaccine design.
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Introduction
CD8+ T cells (TCD8+) of the adaptive immune system limit viral spread in the host by
killing infected cells prior to the release of progeny. Identification of infected cells is
based upon cell surface display of virus-derived peptides (epitopes), usually 8-10 amino
acids in length, in combination with major histocompatibility complex (MHC) class I
molecules (Peaper & Cresswell, 2008; Yewdell, 2007). One remarkable aspect of this
antigen presentation system is the speed with which peptides can be generated by the
intracellular proteolytic machinery following infection. Using peptide appearance at the
cell surface or peptide transport into the ER as a readout, several studies have concluded
that MHC class I-bound peptides are derived primarily from proteins that are degraded
within ∼30 min of their synthesis (Dolan et al, 2009; Princiotta et al, 2003; Reits et al,
2000; Yewdell, 2007), a rate that maximizes the opportunity for TCD8+ to carry out their
effector functions before production and release of viral progeny. Indeed, the implied
half-life of ≤10 min approaches that of so called “N-end rule substrates”, artificially
constructed polypeptides with destabilizing N-terminal amino acids (N-degrons)
(Varshavsky, 1992), whose destruction commences even before synthesis has been
completed (Turner & Varshavsky, 2000). These indirect measures of nascent protein
turnover have been supported by biochemical studies demonstrating that a fraction of the
nascent polypeptide pool rapidly disappears (Schubert et al, 2000; Vabulas & Hartl,
2005; Wheatley, 1984).
Despite intensive study, the bases by which certain copies of nascent protein are
selected for immediate turnover remain poorly understood. In previous studies we
observed that appreciable misfolding imposed by genetic manipulation does not

substantially alter degradation rate and presentation efficiency (Golovina et al, 2005).
This suggested to us that immediate peptide supply is not driven by conventional protein
folding/quality control decisions. The relatively slow pace by which misfolded proteins
are targeted for degradation lends additional support to this notion (Eisenlohr et al, 2007).
In searching for a more potent signal of degradation, we focused on overt hydrophobicity,
exemplified by an unembeded TM domain, as a feature that might require immediate and
decisive action. This was based on the well-known threat that such species pose to cell
viability via aggregate formation and nonspecific association with functional proteins
(Stefani & Dobson, 2003) and the notion that their intractability would be readily
recognized. The experiments reported here support the concept that a high degree of overt
hydrophobicity acts as a signal for immediate degradation and, consequently, peptide
presentation.
The line of investigation that we chose also enabled us to investigate the extent to
which class I peptides are derived from immediately degraded proteins. Of particular
interest in this regard are proteins targeted to the ER, comprising ∼25% of the proteome
(Istrail et al, 2004). These species undergo cotranslational translocation, evaluation by the
quality control machinery and, if rejected, retrotranslocation to the cytosol for
degradation by the proteasome (Vembar & Brodsky, 2008). Collectively, these steps
appear to preclude rapid peptide supply. Our results show substantially prolonged peptide
production from ER targeted proteins compared to their cytosolic counterparts.
In the final series of experiments reported here, overt hydrophobicity and ERtargeting as determinants of peptide supply were concurrently explored in investigating
whether the TM domain of a dislocated ERAD substrate also influences degradation rate

and presentation efficiency. Results not only reinforced the strong effects of these two
attributes, but also provided new insights into the process of ERAD.

Results
TM domain drives cytoTac degradation by the proteasome and enhanced
presentation
A straightforward means of generating unresolvable, overt hydrophobicity is by ablating
the signal sequence of a membrane glycoprotein. This results in default delivery to the
cytosol and an “orphaned” TM domain which the rest of the protein is not configured to
shield. The base construct for these experiments was the human IL-2 receptor alpha
subunit (Tac), a type I membrane glycoprotein to which we appended a triple
hemaglutinin (HA) tag and the OVA257-264 (SIINFEKL) epitope between the signal
sequence and N-terminus of the mature protein (Fig 1A). These additions do not interfere
with proper folding of the ER-directed luminal domain as reactivity with the
conformation-dependent monoclonal Ab 7G7B6 is intact (Golovina et al, 2005). This
construct and all its variants were expressed by recombinant vaccinia viruses. Cells were
infected at 3 pfu/cell for 5 h, with equivalent virus infection that was verified by antivaccinia Ab staining (Supplementary Figure 1A and 2). Consistent with earlier reports
(Golovina et al, 2005; Tobery & Siliciano, 1997; Townsend et al, 1986), elimination of
the signal sequence (creating “cytoTac”) substantially reduced half-life, as assessed by
pulse-chase analysis (Figure 1A and B), and this corresponded with a marked increase in
OVA257-264 presentation as assessed by flow cytometry using the 25-D1.16 OVA257b
264/K -specific

monoclonal Ab (Porgador et al, 1997) (Figure 1C).

To determine whether the exposed TM domain, rather than the luminal domain,
drives rapid degradation of cytoTac, we eliminated the TM domain from cytoTac protein,
generating cytoTac (∆TM). This manipulation resulted in an appreciable increase in

stability (Figure 1A and B) and, consequently, a marked decrease in epitope presentation
compared to cytoTac. These differences were detectable by indirect 25-D1.16 Ab
staining (Figure 1C) and also by direct Alexa 647 conjugated 25-D1.16 Ab staining
(Supplementary Figure 2). This effect was observed at many time points post infection
(Supplementary Figure 1B and C) and also with other cell types (Supplementary Figure
3). The stability of cytoTac (∆TM) is somewhat lower than wild-type Tac protein (Figure
1A) and this does appear to correlate with presentation level (Figure 1C). However the
qualitative differences between the processing of cytosolic and ER-targeted proteins
(Golovina et al, 2002 and below) confounds this kind of comparison. Rapid degradation
of cytoTac was mediated by the proteasome as demonstrated by a short-time pulse
experiment in the presence of the proteasome inhibitor epoxomicin (Figure 1D). After
metabolic labeling, cytoTac protein accumulated in L-Kb cells treated with 1 µM
epoxomicin for 30 min, accounting for approximately 40% and 90% increase compared
to untreated controls at 5 min and 10 min pulse respectively, reflecting a half-life of less
than 10 min. In comparison, no significant accumulation of cytoTac (∆TM) protein
follows treatment with epoxomicin during the short time pulse, further demonstrating the
relative stability of cytoTac (∆TM).
As anticipated from previously reported results (Townsend et al, 1986), both cytoTac
and cytoTac (∆TM) failed to react with the conformation sensitive anti-Tac Ab 7G7B6,
suggesting that both species are misfolded (Figure 2A). This was reinforced by
proteolytic digestion of immunoprecipitated cytoTac and cytoTac (∆TM). Both forms
were similar in terms of trypsin sensitivity and digestion patterns (Figure 2B), and these
patterns were clearly different from that of wild-type, ER-targeted Tac. In addition, both

are completely degraded within a few minutes by proteinase K while Tac is not (results
not shown). Thus, misfolding of the luminal domain is not a powerful driver of rapid
protein degradation.
Confocal immunofluorescence was employed to visualize subcellular location of the
various constructs 6 h post infection (Supplementary Figure 4). While cytoTac (∆TM) is
diffusely distributed throughout the cell, cytoTac appears to localize to the ER membrane.
This is not unexpected since it has been reported that access to the cytosolic face of the
ER is required for the degradation stimulated by hydrophobicity (Metzger et al, 2008).
Notably, there is no evidence of aggregate formation, a potentially complicating factor,
by any of the proteins. The proteasome sensitivity of cytoTac also argues against the
disappearance of the protein in biochemical studies being due to the formation of
detergent-insoluble aggregates.
cytoTac and cytoTac (∆TM) are processed via the conventional pathway
Conventional class I-restricted antigen processing involves degradation by the
proteasome and transport into the ER via the transporter of antigenic peptides (TAP)
(Yewdell et al, 2003). Since alternatives to both steps have been described (GilTorregrosa et al, 1998; Lautscham et al, 2001; Snyder et al, 1997), it was important to
determine whether the difference between the processing of cytoTac and cytoTac (∆TM)
could be due to processing via distinct pathways. Treatment with 3 µM proteasome
inhibitor epoxomicin prior to a 5-h infection substantially reduced presentation of the
OVA257-264 epitope from either substrate (Figure 3A) but not presentation of a minigene
product which does not require processing. In addition, TAP-/- B6 cells were completely
unable to present the OVA257-264 epitope from any of the three Tac-based contexts 5 h

post infection (Figure 3B). In contrast, a minigene product that is targeted to the ER via
signal sequence-mediated translocation (ss-m/S), thereby obviating TAP function, was
presentable by TAP-/- cells. Thus, both TM-intact and TM–ablated constructs are
processed via the classical MHC class I pathway.
cytoTac is processed with the same kinetics as cytoTac (∆TM)
Given its relative stability, cytoTac (∆TM) represents a typical cytosolic protein that is
subjected to only the enigmatic system of basal antigen processing (which we propose to
be driven by processes other than standard quality control decisions). Thus, peptides were
expected to be generated from the cohort of cytoTac (∆TM) that is degraded within 30
min of production. This was tested according to established methods (Princiotta et al,
2003); cells were infected with recombinant vaccinia expressing cytoTac (∆TM) and the
accumulation of OVA257-264/Kb complexes at the cell surface was documented by flow
cytometry. At 3 h post infection, the protein synthesis inhibitors cycloheximide and
emetine were added at 25 µg/ml each, resulting in depletion of processing substrate and a
subsequent leveling off of surface complexes. The delay between addition of inhibitors
and cessation of complex accumulation was ∼60 min (Figure 4A), consistent with a ∼30
min lifespan after taking post-proteasomal steps into account (Princiotta et al, 2003).
When the TM domain containing cytoTac was similarly analyzed, the cycloheximide
delay time was identical (Figure 4B). Thus, peptides from both cytosolic proteins are
derived from rapid degradation of nascent proteins, with the additional product from
cytoTac being stimulated by overt hydrophobicity of the orphaned TM domain that drives
antigen processing at the same high rate as the basal system.
The orphaned TM domain is a dose-dependent degradation signal

Exposed hydrophobicity in other systems has been reported to act as a degradation signal
(Arteaga et al, 2006; Gilon et al, 1998; Johnson et al, 1998). The results thus far
suggested to us that the orphaned TM domain acts in the same capacity. We tested the
notion that the orphaned TM domain acts as a bona fide degradation signal (“degron”) in
three different ways. First, we speculated that the degree of hydrophobicity, as governed
by the length of the domain, might determine the strength of signal. Thus, we
progressively truncated the TM domain by removing six or thirteen amino acids from the
C-terminus of the 19-residue domain (Figure 5A). Indeed, protein stability was
proportional to the length of the TM domain (Figure 5A and B). Likewise, a graded
diminution in OVA257-264 epitope presentation was also observed (Figure 5C). Second, we
expected that the TM domain would act independently of its position within Tac.
Accordingly, we moved the TM domain from its original location near the C-terminus to
the N-terminus. This resulted in a level of protein degradation and OVA257-264
presentation that was comparable to cytoTac (Figure 5D-F). Finally, we anticipated that
the TM domain should have a similar effect when transferred to a different cytosolic
protein. We therefore appended the Tac TM domain to the N- or C-terminus of an HAtagged, OVA257-264-containing cytosolic version of influenza nucleoprotein (NP13-498)
(Figure 6A). Addition in either location resulted in rapid degradation of the NP-based
protein (Figure 6A and B) and much higher levels of surface OVA257-264/Kb complexes
compared to the unmodified NP13-498 protein (Figure 6C). In previous work we deduced
that sequences could be added to the N-terminus of NP13-498 without disturbing folding
(Golovina et al, 2005). This also appeared to be the case with TM added to the Nterminus of NP13-498 since this construct is immunoprecipitated by two different NP-

specific monoclonal Abs (Supplementary Figure 5). Thus misfolding appears not to be
mandatory for rapid peptide supply. Due to the availability of a previously generated
recombinant vaccinia (Golovina et al, 2005), these NP-based substrates provided the
opportunity to assess the relative strengths of the TM domain and an N-degron, the latter
being well known for its potency. Indeed, the N-end rule substrate was most rapidly
degraded (Figure 6D) and generated the highest levels of epitope (Figure 6E), but the TM
degron was also well above the control construct.
Vaccinia infection is profoundly disruptive to cellular organization, ultimately leading
to cell death. To determine whether such disruption in some way contributes to the drive
toward immediate degradation, we expressed the Tac-based model antigens via
transfection. L-Kb cells were transfected with the same amount of various pIRES2-EGFP
constructs and then cultured in the absence or presence of the proteasome inhibitor
MG132 (Supplementary Figure 6). In the absence of MG132, the cytoTac band is barely
visible, whereas both Tac and cytoTac (∆TM) bands are easily detected. However,
cytoTac accumulated to the same extent as cytoTac (∆TM) after proteasome inhibition.
Thus, the impact of overt hydrophobicity is not peculiar to the virally infected cell.
Peptide production from an ER-targeted protein is substantially delayed
Experiments thus far concentrated upon cytosolic proteins from which immediate peptide
supply was readily appreciable (Figure 4A and B). Considering the various steps
involved in ERAD (Meusser et al, 2005), we imagined that slower kinetics might apply to
ER-targeted proteins. Thus, we carried out the same experiments with wild-type (ERtranslocated) Tac that had been carried out for the cytosolic counterparts, measuring the
delay between addition of protein synthesis inhibitors at 3 h post infection and the

termination of peptide/MHC complex delivery to the cell surface. As anticipated, peptide
production was substantially more prolonged (Figure 4C). These kinetics data are
consistent with the reduced levels of surface epitope from Tac vs. cytoTac (Figure 1C).
TM domain is a driver for ERAD and membrane protein presentation
In light of our findings with cytosolic proteins, we considered the possibility that the
destruction rates of membrane glycoproteins undergoing ERAD are influenced by the
TM domain that is orphaned upon retrotranslocation. To investigate this we generated
Tac (∆TM), an ER-targeted, untethered protein, and similarly analyzed peptide
production kinetics (Figure 4D). While peptide display from wild-type Tac plateaued at 2
to 2.5 h post cycloheximide treatment, peptide from Tac (∆TM) continued to accumulate
at 3 h post treatment.
These kinetics experiments were complemented with biochemical analysis. We first
ascertained that such ERAD intermediates of our nominal antigens could be visualized by
immunoblotting analysis. Following their retrotranslocation ERAD substrates are
deglycosylated prior to proteasomal destruction (Romisch, 2005). Cells expressing wildtype Tac in the presence of the reversible proteasome inhibitor MG132 accumulated a
species with mobility similar to that of cytoTac (Supplementary Figure 6) and mature Tac
treated with Endoglycosidase H (Endo H) (Figure 7B), consistent with removal of the
signal sequence and absence of sugar groups. Because this species could be either nascent
Tac that had not yet been glycosylated (unglycosylated) or retrotranslocated Tac that had
been deglycosylated, the protein synthesis inhibitor emetine was added 10 min prior to
lysis in a detergent-containing buffer to clear any unglycosylated Tac. A similar species
was observable when we expressed Tac (∆TM). Clearing the majority of glycoproteins

from the cell lysates with ConA sepharose 4B aided in visualization of these minor
deglycosylated

degradation

intermediates

(Figure

7A,

right

panel).

Thus,

retrotranslocated and deglycosylated ERAD substrates were readily visualized with
addition of proteasome inhibitor.
In order to determine relative degradation rates of these intermediates, similar
conditions were employed but then MG132 was withdrawn and the cells were incubated
for varying times prior to lysis and removal of glycosylated species by Con A beads. Due
to limited sensitivity of metabolic pulse for visualization of the minor ERAD species
(Supplementary Figure 7), the protein synthesis inhibitor-chase assay followed by
immunoblotting analysis was employed for tracking the fate of the deglycosylated
species following withdrawal of reversible proteasome inhibitor. As shown in Figure 7C,
the proteasome substrate fraction derived from Tac protein disappeared more rapidly than
that from Tac (∆TM) protein following MG132 withdrawal. Indeed, the rate difference
was comparable to that observed for the cytosolic substrates (Figure 1A). This
observation was not peculiar to viral infection as comparable results were obtained from
a transfection system (Supplementary Figure 8). In contrast, the glycosylated species,
representing mature folded proteins that have passed quality control, are quite stable
during the period of 60-min chase (Supplementary Figure 9). As with cytoTac,
stabilization of the ERAD substrates by proteasome inhibitor (Figure 7A) argues against
the possibility that disappearance of the Tac ERAD intermediate is due to formation of
detergent insoluble aggregates. This conclusion is also supported by the confocal images
(Supplementary Figure 4) that show no evidence of aggregate formation. Interestingly,
high molecular weight polyubiquitin species were present in the ERAD fractions from

both Tac and Tac (∆TM) proteins (Supplementary Figure 10), suggesting that the
orphaned TM domain, not the process of polyubiquitination, is a more potent determinant
of rapid degradation.
We further explored the influence of the dislocated TM domain on ERAD with
another type I membrane protein, influenza hemaglutinin (HA), which was expressed in
wild-type, TM-ablated and cytosolic (signal sequence-ablated) forms. As observed
previously (Townsend et al, 1986), cytoHA is subject to rapid turnover and, as with
cytoTac, this form of HA is considerably stabilized by proteasome inhibition (Figure 7D).
Further, an ERAD intermediate of wild-type HA with mobility identical to that of
cytoHA (Figure 7D) and deglycosylated HA (Supplemental Figure 11) became apparent
with exposure to proteasome inhibitor. Most important, this intermediate was turned over
at a faster rate compared to its ∆TM counterpart, as indicated by its relatively greater
accumulation in the presence of MG132 (Figure 7D) and faster degradation following
withdrawal of MG132 (Figure 7E). Thus, orphaned TM domains resulting from ERAD
can also increase the degradation rate, thereby enhancing peptide supply.

Discussion
It has been known for several decades that a fraction of the nascent protein pool is
subjected to immediate degradation (Wheatley et al, 1980), perhaps as a way of ensuring
immediate amino acid availability for rapid adjustment of the proteome in response to
environmental changes (Wheatley, 1984). An obvious benefit of immediate turnover is
the rapid display of MHC/peptide complexes at the surface of the infected cell, allowing
for CD8+ T cell recognition and effector function prior to release of progeny. While there
is some debate about the size of nascent protein pool that is subjected to this fate
(Schubert et al, 2000; Vabulas & Hartl, 2005; Wheatley et al, 1980), even lower estimates
are more than sufficient for CD8+ T cell recognition, which is extremely sensitive
(Wherry et al, 1999; Zook et al, 2006).
Despite intensive investigation, the basis for rapid peptide supply has remained
elusive. Indeed, to this point only N-end rule substrates have been known to approximate
the speed with which the first wave of peptides are produced following viral infection.
However, N-degrons appear to be utilized under selective conditions (Varshavsky, 1992)
and are generally non-functional in eukaryotic cells (Gueguen & Long, 1996; Wong et al,
2004). Thus, the bulk of rapid peptide supply is likely driven by other signals. Here we
provide evidence that overt hydrophobicity of sufficient density can provide such a signal.
The favored explanation for rapid peptide supply is the DRiP (Defective Ribosomal
Products) model which proposes that production of any protein is an imperfect process,
and that recognition of defective copies drives immediate degradation (Yewdell et al,
1996). We have expressed some reservations with the original iteration of this model
(Eisenlohr et al, 2007) because most, if not all, quality control decisions that have been

investigated appear to operate with kinetics that are slower than those associated with
rapid peptide supply. Further, we have made several mutations to nominal antigens that
cause misfolding and these do not appreciably alter the level of antigen processing
(Golovina et al, 2005). Consequently, we have proposed an alternative model in which
copies of nascent cytosolic protein are selected for a basal level of degradation
independent of quality control decisions (Eisenlohr et al, 2007). Specifically, we have
suggested that the minor fraction of the nascent protein pool that is produced by
ribosomes lacking their associated chaperones (Raue et al, 2007) is immediately degraded
since unshielded hydrophobicity represents a substantial danger to the cell (Wickner et al,
1999). This model is supported by the results reported here and may also provide the
mechanistic basis for an updated version of the DRiP model which has proposed the
existence of “immunoribosomes”, ribosome variants that generate a high proportion of
DRiPs (Yewdell & Nicchitta, 2006). The key point in our model is that most nascent
polypeptides are not inherently defective (the linear sequence is correct) and that
defectiveness might be considered to lie more with the ribosome and its associated
chaperones. In practical terms, this could strongly influence strategies for enhancing
rapid peptide production.
Our results shed new light on the landmark publication of Townsend et al, who
reported that redirecting influenza hemagglutinin (HA) to the cytosol by genetic ablation
of the signal sequence resulted in accelerated turnover and substantially enhanced peptide
presentation (Townsend et al, 1986), a finding that initiated focus on rapid peptide supply
(Townsend et al, 1988). The default explanation for the result is misfolding of cytosolic
HA due to lack of glycosylation and disulfide bonding. However, our results indicate that

the unembedded TM domain is the more potent driver. The targeting of viral or tumor
antigens for rapid cytosolic degradation has been reported to enhance CD8+ CTL
responses (Tobery & Siliciano, 1999; Tobery & Siliciano, 1997). Thus, the novel
degradation signal we have identified is expected to impact CD8 T cell responses in vivo.
Exposed hydrophobicity has been previously reported to stimulate degradation
(Arteaga et al, 2006; Gilon et al, 1998; Johnson et al, 1998), but our study appears to be
the first report of a TM domain acting in this capacity and of the impact on peptide
supply. While we first made this observation using an artificial cytosolic protein with an
ablated signal sequence, we subsequently demonstrated the impact upon ERAD. We are
currently testing two additional mechanisms by which orphaned hydrophobicity may
drive the rapid turnover of cytosolic proteins. First is the unchaperoned nascent
polypeptide model described above. Second is the mistargeting of a membrane
glycoprotein to the cytosol due to lack of signal recognition particle engagement. This is
not necessarily a rare event, depending upon the particular signal sequence and level of
cellular stress (Kang et al, 2006). Indeed, it has been reported that an epitope which
contains the cleavage site of the ER signal peptidase is efficiently presented to MHC
class I molecules, implying a pathway for processing ER-targeted proteins prior to
translocation into the ER lumen (Schlosser et al, 2007). Other potential mechanisms for
the generation of overt hydrophobicity include endoproteolysis that separates a
hydrophobic segment from the domain that normally shields it and premature termination
of translation that could achieve the same effect.
The observation that degradation rate and, consequently, peptide supply is
proportional to the length of the TM domain suggests a triaging system that may be

essential for cell survival. Certain acute stresses cause immediate and widespread protein
unfolding to which there is a rapid, programmed response (Hartl et al, 1994). Our results
suggest that those unfolded proteins with the greatest degree of overt hydrophobicity,
representing the greatest threat, would be selected for most rapid disposal.
The ability of a TM domain to accelerate ERAD was not necessarily predictable
considering the fundamental topological differences between ERAD and cytosolic
degradation. An important aspect of ERAD revealed by our results is that degradation
rate can be impacted by properties that are distinct from those that initiate ERAD, such as
folding state of the luminal domain (Carvalho et al, 2006). Our results are seemingly at
odds with a recent report that two canonical transmembrane-anchored ERAD substrates
are turned over less quickly than their untethered counterparts (Bernasconi et al). One
potential explanation is that we focused on only the latter stages of ERAD, and the TM
domain might have a larger negative impact on other stages of ERAD. However, the
relative rates of peptide production from Tac and Tac (∆TM), as determined by all stages
of ERAD, suggest that this is not the case for the Tac-based proteins that we studied.
Another consideration is that our model proteins are likely subjected to ERAD based
upon a variety of defects. The model proteins of Bernansconi et al. are essentially
uniform in their defectiveness and may not represent most stochastically generated Tac
defects. Further, in the earlier study, 100% of the model substrates expressed at high
levels were subjected to ERAD. This pressure on the system may impact the steps in the
process that are rate limiting. Further exploration of these issues could have important
ramifications for therapeutic approaches to the many inherited human diseases that are
ERAD-based (Gregersen et al, 2006).

A second point emerges from our ERAD studies; while peptides are certainly
generated from very short-lived (< 30 min) proteins, this need not be the case as
evidenced by the prolonged processing of our ER-targeted substrates. This is contrary to
previous reports that estimate a lifetime of 30 min or less for all or the bulk of proteins
that contribute to peptide supply (Princiotta et al, 2003; Reits et al, 2000). The timing we
observed is consistent with conventional ERAD which features a quality control step
prior to retrotranslocation (Vembar & Brodsky, 2008) and is the embodiment of the DRiP
model in any form. This notion is supported by an earlier report on the ER-targeted
protein tyrosinase, whose efficiency of presentation was enhanced by misfolding
mutations and decreased by treatment with chemical chaperones (Ostankovitch et al,
2005). We speculate that the more limited time windows deduced by earlier reports were
due, in one case, to the processing substrates chosen for analysis (Dolan et al, 2009;
Princiotta et al, 2003; Qian et al, 2006) and, in the other, to relative insensitivity of the
assay employed (Reits et al, 2000). Indeed, the current DRiP model recognizes the
heterogeneous nature of processing substrates and their wide range of degradation rates
(Yewdell, 2007). Our results suggest that immediate peptide supply is limited to cytosolic
processing substrates which may, therefore, contribute the earliest targets for CD8+ T cell
recognition of the infected cell.
These studies add insight into fundamental aspects of intracellular proteolysis,
thereby shedding new light on the forces involved in MHC class I-restricted peptide
supply. In turn, this information could provide new approaches to the design of vaccines
that are intended to optimize CD8+ T cell-based protection.

Materials and Methods
Cell lines, antibodies and reagents
L-Kb (L929 stably transfected with H-2Kb), TAP-/- B6 fibroblast cells, MC57G, RMA,
RMA-S and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% fetal bovine serum (FBS). Anti-HA tag Ab (clone 12CA5) was
purchased from Roche; anti-actin Ab from Sigma-Aldrich; anti-BiP Ab from Abcam.
Anti-B5R Ab and Alexa 647 conjugated 25-D1.16 Ab were generously provided by the
laboratory of Drs. J. W. Yewdell and J. R. Bennink (NIAID). CM1-1.2 is a mouse Ab
that is specific for HA S1 (Chianese-Bullock et al, 1998), and 7G7B6 is a conformationsensitive mouse Ab that is specific for Tac protein (Golovina et al, 2005). General
chemical supplies were obtained from Sigma-Aldrich unless otherwise specified.
Recombinant vaccinia viruses
The recombinant vaccinia viruses encoding Tac, cytoTac, NP13-498, m/OVA257-264, a
control construct without OVA257-264 and PR8 hemagglutinin (HA) have been previously
described (Eisenlohr et al, 1992; Golovina et al, 2005). Other constructs were generated
by standard PCR to manipulate the TM domain or the signal sequence in the base
constructs. Generation and titration of recombinant vaccinia virus was conducted as
described (Eisenlohr et al, 1992). Cells were infected for 1 h at 37°C with vaccinia
viruses in balanced salt solution (BSS) containing 0.1% BSA. After 1 h, DMEM plus 5%
FBS was added and the cells were incubated for the reminder of the assay.
Metabolic labeling and immunoprecipitation
L-Kb cells were infected with antigen-expressing viruses at 3 pfu/cell for 3 h, and then
pulse-labeled with

35

S-labeling mix (MP Biomed) for 10 min. In some experiments, the

pulse assay was carried out in the presence of the irreversible proteasome inhibitor
epoxomicin (Boston Biochem) at 1 µM for 30 min before 35S-labeling. To chase protein
degradation, the labeling medium was removed and the cells were cultured in normal
medium. At the indicated time points, aliquots were washed with PBS and lysed in a lysis
buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5 mM
phenylmethylsulfonyl fluoride (PMSF) and the protease inhibitor cocktail. Cell extracts
were incubated with specific Abs bound to protein A agarose (Thermo) at 4°C for 4 h.
Precipitated proteins were resolved by 10% SDS-PAGE and analyzed using Typhoon
9400 scanner (Amersham). Band intensities were quantified using ImageQuant software
(Amersham).
Antigen presentation analysis
Cells infected with antigen-expressing viruses at 3 pfu/cell for 5 h were stained for
OVA257-264/Kb complexes on the surface with 25-D1.16 Ab (Porgador et al, 1997)
followed by fluorescein-conjugated anti-mouse IgG Ab (Vector Lab), and then fixated in
2% paraformaldehyde (Electron Microscopy Sciences) in PBS. In some experiments,
cells were treated with proteasome inhibitor epoxomicin (3 µM) for 30 min prior to virus
infection. The mean fluorescent intensity (MFI) was measured using Epics XL (Beckman
Coulter) or FACSCalibur (BD Biosciences) flow cytometers.
Limited proteolysis
The cells were metabolically labeled and disrupted with lysis buffer (20 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% Triton X-100). The constructs were immunoprecipitated with
anti-HA Ab. Protease susceptibility of model antigens was determined by incubation with
5 µg/ml trypsin. After the indicated time of incubating on ice, aliquots were removed and

5 mM PMSF was added to stop the reactions. Proteolytic fragments were separated by
12% SDS-PAGE gel and visualized by autoradiography.
Kinetics of peptide display after antigen synthesis
L-Kb cells were infected with antigen-expressing viruses at 3 pfu/cell. After 3 h, infected
cells were treated with protein synthesis inhibitors cycloheximide and emetine (25 µg/ml
each). Aliquots were taken at the indicated time points and subjected to antigen
presentation analysis using 25-D1.16 Ab.
Immunoblotting
Cells were lysed in Tris-buffered saline containing 1% Triton X-100, protease inhibitor
cocktail, and PMSF. Cell lysates were separated by SDS-PAGE and transferred to
nitrocellulose membranes. After blocking with 5% nonfat milk, the protein bands were
detected using primary Abs, peroxidase-labeled secondary Abs (Vector Lab) and a
chemiluminescence detection kit (Kirkegaard & Perry Laboratories), according to the
manufacturer’s instructions. All blots were re-probed with loading (anti-actin Ab).
Endoglycosidase digestion
Cell extracts were divided into two equal portions, which were then incubated with or
without endoglycosidase H (Endo H; New England Biolabs) for 2 h at 37°C. The reaction
mixtures were analyzed by immunoblotting using the indicated Abs.
ERAD substrate degradation
L-Kb cells were infected with recombinant vaccinia viruses for 1 h and then for 3 h in the
presence of the reversible proteasome inhibitor MG132 (10 µM, Sigma-Aldrich) to allow
the minor ERAD substrate fraction to accumulate. 10 min prior to MG132 withdrawal,
the irreversible protein synthesis inhibitor emetine (50 µg/ml) was added to shut down

additional protein synthesis. After washing with normal medium, cells were cultured in
the absence of MG132. At the indicated time points, aliquots were washed with PBS and
the cells were solubilized with lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1% Triton X-100, 5 mM N-ethylmaleimide (NEM) to prevent deubiquitination of
proteins, 0.5 mM PMSF and the protease inhibitor cocktail. Cell extracts were incubated
with Con A sepharose 4B (Amersham) overnight at 4°C to remove the glycoproteins. The
supernatants were resolved by SDS-PAGE and subsequent immunoblotting.
Expression plasmids and transfection
The Tac-based model antigens were subcloned from the pSC11-based vaccinia virus
recombination vectors into the eukaryotic expression vector pIRES2-EGFP (Clontech).
Transient transfection of L-Kb cells was performed using Lipofectamine 2000
(Invitrogen). The cells were incubated for 16 h before treatment with proteasome
inhibitor MG132 (10 µM) for an additional 8 h.
Statistical analysis
Data are expressed as means ± S.D. and evaluated by Student’s t-test. To identify the
differences in the presentation kinetics, a first-order autocorrelation covariance structure
was used to model the correlation among repeated measures over time. Analysis was
performed using SAS software version 9.2 (SAS Institute). The threshold p-value
required for significance was 0.05.
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Figure legends
Figure 1 Impact of the orphaned TM domain on cytoTac degradation and MHC class I
epitope presentation. (A) Schematic representation of Tac-based model antigens. SS,
signal sequence; HA, HA-tag; S, OVA257-264; TM, transmembrane. Right panel,
metabolic pulse-chase of infected cells followed by immunoprecipitation with anti-HA
Ab to determine the stability of Tac-based proteins. (B) Stability of the model antigens
quantified by phosphoroimaging analysis. Data represent the mean and S.D. from three
independent experiments. (C) OVA257-264 presentation from Tac-based antigens in a 5-h
infection assay, as assessed by staining of surface OVA257-264/Kb complexes with 25D1.16 Ab. Error bars represent the S.D. of triplicate samples. This experiment was
repeated at least three times with similar results. (D) Metabolic pulse assay in the absence
or presence of proteasome inhibitor epoxomicin (1 µM). Right panel, phosphoroimager
quantification of relative amounts of proteins. Data represent the mean and SD from three
independent experiments.

Figure 2 Folding status of the model antigens. (A) The folding status was evaluated in
virus-infected L-Kb cells by metabolic labeling and immunoprecipitation with
conformation-insensitive (anti-HA) and conformation-sensitive (anti-Tac clone 7G7B6)
Abs. (B) Limited proteolysis to study protein conformation. Virus-infected L-Kb cells
were metabolically labeled, and the constructs were immunoprecipitated with anti-HA
Ab prior to proteolysis with 5 µg/ml trypsin for 0-60 min on ice. The resulting digests
were analyzed using 12% SDS-PAGE. The stars indicate the position of the full-length
model antigens. Right panel, stability of the different full-length species quantified by

phosphoroimaging analysis. All images are representative of two independent
experiments.

Figure 3 OVA257-264 presentation from Tac-based proteins via the classical MHC class I
pathway. (A) OVA257-264 presentation from L-Kb cells infected with the indicated viruses
at 3 pfu/cell for 5 h in the presence or absence of epoxomicin (3 µM). A vaccinia virus
that expresses the SIINFEKL-encoding mini-gene at limiting amounts via a 5’ UTR
hairpin technique (m/S-HP18) (Wherry et al, 1999) was used as a toxicity control to
confirm that there was no effect upon proteasome-independent presentation. Data are
representative of three independent experiments. (B) OVA257-264 presentation from TAPdeficient B6 fibroblast cells (H-2b haplotype) infected with the indicated viruses at 3
pfu/cell for 5 h. A vaccinia virus that expresses the SIINFEKL-encoding mini-gene
targeted to the ER independent of TAP function via signal sequence-mediated
translocation, ss-m/S, was used as a control to show processing and presentation
capability via a TAP-independent pathway. Data are representative of three independent
experiments.

Figure 4 Kinetics of OVA257-264 presentation. OVA257-264 presentation from L-Kb cells
infected with antigen-expressing viruses and treated with protein synthesis inhibitors (PSI)
at 3 h post infection. Data represent the mean and S.D. from three independent
experiments. (A) cytoTac (∆TM). (B) cytoTac. (C) membrane-bound Tac. (D) soluble
Tac (∆TM). The slopes for the two ER-targeted constructs (C and D) are essentially
identical after 1.5 h but statistically distinct up to 1.5 h post PSI treatment (p <0.0001).

Figure 5 The orphaned TM domain as a degradation signal in cytoTac variants. (A)
cytoTac variants with a truncated TM domain. HA, HA-tag; S, OVA257-264; TM,
transmembrane. Right panel, metabolic pulse-chase of cytoTac variants with a truncated
TM domain. (B) Stability of the model antigens quantified by phosphoroimaging analysis.
Data represent the mean and S.D. from three independent experiments. (C) OVA257-264
presentation from cytoTac proteins with a truncated TM domain in a 5-h infection assay.
Error bars represent the S.D. of triplicate samples. This experiment was repeated three
times with similar results. (D) cytoTac variant with a relocated TM domain. HA, HA-tag;
S, OVA257-264; TM, transmembrane. Right panel, metabolic pulse-chase of cytoTac
protein with a relocated TM domain. (E) Stability of the model antigens quantified by
phosphoroimaging analysis. Data represent the mean and S.D. from three independent
experiments. (F) OVA257-264 presentation from cytoTac proteins with a relocated TM
domain in a 5-h infection assay. Error bars represent the S.D. of triplicate samples. This
experiment was repeated three times with similar results.

Figure 6 Transfer of the Tac TM domain to another model antigen. (A) NP13-498-based
model antigens. HA, HA-tag; S, OVA257-264; TM, Tac transmembrane. Right panel,
metabolic pulse-chase of NP13-498-based proteins. (B) Stability of the model antigens
quantified by phosphoroimaging analysis. Data represent the mean and S.D. from three
independent experiments. (C) OVA257-264 presentation from NP13-498-based proteins in a
5-h infection assay. Error bars represent the S.D. of triplicate samples. This experiment
was repeated three times with similar results. (D) Metabolic pulse-chase of N-end rule

substrate of NP13-498 protein, Ub-R-NP13-498. Bottom panel, stability of Ub-R-NP13-498
quantified by phosphoroimaging analysis. Data represent the mean and S.D. from two
independent experiments. (E) OVA257-264 presentation from NP13-498 proteins appended
with a degradation signal (TM or N-degron) in a 5-h infection assay. Error bars represent
the S.D. of triplicate samples. This experiment was repeated three times with similar
results.

Figure 7 Contribution of the orphaned TM domain to ERAD. (A) Immunoblotting
analysis of proteasome substrates from ER-targeted Tac proteins before (left panel) and
after (right panel) removing the majority of glycosylated species by Con A sepharose 4B
beads. (B) Endo H sensitivity of MG132-treated samples after clearance of most
glycosylated species by Con A separation, illustrating the shift of the residual
glycosylated species to proteasome substrates. (C) Degradation of accumulated
proteasome substrates following 10-min emetine treatment and withdrawal of MG132.
Cells were incubated for varying times prior to lysis, clearance of glycosylated species,
and analysis via immunoblotting. Stars indicate the positions of the ERAD intermediates.
Right panel, stability of the ERAD substrates quantified by densitometric analysis. Data
represent the mean and S.D. from two independent experiments. (D) Proteasome
substrates from HA-based proteins in L-Kb cells infected with virus recombinants for 4 h
and detected by immunoblotting with anti-HA S1 Ab. (E) Degradation of accumulated
proteasome substrates from two HA proteins in L-Kb cells infected with virus
recombinants for 18 h in the presence of MG132. Following 10-min emetine treatment
and withdrawal of MG132, cells were incubated for varying times prior to

immunoblotting analysis. Stars indicate the positions of the ERAD intermediates for HA
and HA (∆TM). Right panel, stability of the ERAD substrates quantified by densitometric
analysis. Data represent the mean and S.D. from two independent experiments. All blots
are representative of 2-3 independent experiments.
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